drugset / Trial / NCT06922318
The COSMYC Trial (COmbined Suppression of MYC)
Phase 2
Recruiting
50 enrolled
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
National Cancer Institute (NCI) · collabZenith Epigenetics · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This research is being done to determine if receiving the combination of testosterone and ZEN-3694 followed by the combination of enzalutamide plus ZEN-3694 will decrease the size of tumors in patients with prostate cancer that has become resistant to castration and other therapies. The investigators also want to determine if dosing first with the combination of testosterone and ZEN-3694 may cause enzalutamide and ZEN-3694 to work more effectively.
Timeline
- Start
- 2025-08-19
- Primary completion
- 2031-08-30
- Completion
- 2031-08-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Enzalutamide | Other / unclassified | 160 mg | Oral |
| Subject | Testosterone Cypionate | Small molecule | 400 mg | Intramuscular |
| Subject | ZEN-3694 | Small molecule | 36 mg | Oral |
| Subject | ZEN-3694 | Small molecule | 72 mg | Oral |
| Background | Decapeptyl | Unknown | — | — |
| Background | Degarelix | Other / unclassified | — | — |
| Background | Goserelin | Other / unclassified | — | — |
| Background | Leuprolide | Other / unclassified | — | — |
| Background | Relugolix | Small molecule | — | — |